An argenx representative will contact you soon, so keep an eye on your inbox.
†Data collected from a qualitative, cross-sectional, non-interventional study in 28 people who reported receiving at least one treatment for gMG. Eligible participants were US residents, ≥18 years old, and comfortable reading and communicating in English. Study excluded people with only ocular disease to better understand the breadth of MG symptoms that affect all muscle groups.
gMG=generalized myasthenia gravis; MG=myasthenia gravis.
gMG is a chronic, debilitating, IgG-mediated autoimmune disease that causes intense fluctuating muscle weakness that can result in:
gMG=generalized myasthenia gravis; IgG=immunoglobulin G.
The MG-ADL scale is an easy-to-use tool that assesses 8 functions typically affected in gMG and allows you to quantify your patients' symptoms. Each function is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.1,11,12‡
‡Data was collected from 45 patients who were starting immunomodulatory treatment for MG for the first time who did not have other medical conditions that would interfere with treatment with prednisone or IVIG or that the investigator considered important. Pregnant or breastfeeding individuals were excluded.
gMG=generalized myasthenia gravis; IVIG=intravenous immunoglobulin; MG=myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living.
gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living.
References: 1. Muppidi S et al. Muscle Nerve. 2022;65(6):630-639. doi:10.1002/mus.27476 2. Mantegazza R, Antozzi C. Front Neurol. 2020;11. doi:10.3389/fneur.2020.00981 3. Nair SS, Jacob S. Immunotargets Ther. 2023;12:25-45. doi:10.2147/itt.s377056 4. Sánchez-Tejerina et al. J Clin Med. 2022;11(21):6394. doi:10.3390/jcm11216394 5. Jackson K et al. Neurol Ther. 2023;12(1):107-128. doi:10.1007/s40120-022-00408-x 6. Gilhus NE et al. Nat Rev Neurol. 2016;12(5):259-268. doi:10.1038/nrneurol.2016.44 7. Gilhus NE. N Engl J Med. 2016;375(26):2570-2581. doi:10.1056/NEJMra1602678 8. Rødgaard A et al. Clin Exp Immunol. 1987;67(1):82-88. 9. Behin A, Le Panse R. J Neuromuscul Dis. 2018;5(3):265-277. doi:10.3233/JND-170294 10. Twork S et al. Health Qual Life Outcomes. 2010;8:129. doi:10.1186/1477-7525-8-129 11. Wolfe GI et al. Neurology. 1999;52(7):1487-1489. doi:10.1212/wnl.52.7.1487 12. Diez Porras L et al. J Clin Med. 2022;11(8):2189. doi:10.3390/jcm11082189
An argenx representative will contact you soon, so keep an eye on your inbox.
We’re looking forward to sharing information about innovations in gMG with you. Keep an eye on your inbox for important updates on Raising the Bar in gMG.
gMG=generalized myasthenia gravis.